Evidence map›Paper›PMID 42764801›Full record

ArticleFuture medicinal chemistry2026

Antifungal metallacarboranes modulate Hsp90 activity.

Konrad Kubiński, Paweł Czubak, Aleksandra Martyna, Paweł Kozyra, Paulina Czaplewska, Sonja Engler, Johannes Buchner, Krzysztof Fink, Tomasz Goszczyński, Maciej Masłyk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Konrad KubińskiDepartment of Molecular Biology, The John Paul II Catholic University of Lublin, Lublin, Poland.
Paweł CzubakDepartment of Molecular Biology, The John Paul II Catholic University of Lublin, Lublin, Poland.
Aleksandra MartynaDepartment of Molecular Biology, The John Paul II Catholic University of Lublin, Lublin, Poland.
Paweł KozyraDepartment of Biomedical and Analytical Chemistry, The John Paul II Catholic University of Lublin, Lublin, Poland.
Paulina CzaplewskaLaboratory of Mass Spectrometry-Core Facility Laboratories, Intercollegiate Faculty of Biotechnology of UG and MUG, University of Gdansk, Gdansk, Poland.
Sonja EnglerTUM - School of Natural Sciences, Center for Protein Assemblies - CPA, Garching, Germany.
Johannes BuchnerTUM - School of Natural Sciences, Center for Protein Assemblies - CPA, Garching, Germany.
Krzysztof FinkLaboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Tomasz GoszczyńskiLaboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Maciej MasłykDepartment of Molecular Biology, The John Paul II Catholic University of Lublin, Lublin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDespite growing interest in metallacarborane biological activity, the molecular targets underlying their antifungal activity remain unknown. This study aimed to identify protein targets of antifungal metallacarborane derivatives in EXPERIMENTAL: Affinity chromatography using chromatographic beads bearing immobilized [CoSAN-I]

resultsMALDI-TOF analysis identified 72 interacting proteins, of which 14 are established antifungal targets; Hsp90 showed the highest sequence coverage (82.7%). SPR confirmed direct, multivalent binding of all metallacarborane derivatives to Hsp90. The compounds modulated Hsp90 activity in a biphasic, dose-dependent manner, with maximal activation of 82-107% at 50-75 µM.

conclusionsMetallacarboranes directly engage and functionally modulate Candida albicans Hsp90, establishing a novel mechanistic basis for their antifungal activity and providing a rational framework for the development of boron-cluster-based therapeutics.

Indexed as

Antifungal AgentsBoron CompoundsCandida albicansHSP90 Heat-Shock ProteinsMicrobial Sensitivity TestsMolecular Docking SimulationSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStructure-Activity RelationshipAntifungal AgentsBoron CompoundsHSP90 Heat-Shock Proteinsantifungal agentsboron clustersCandida albicansHsp90Metallacarboranes

Identifiers

PMID42764801
PMCPMC13641588

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.